94789-37-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyrimidinecarbonitrile, 4-methoxy(6CI,9CI) is used as a chemical intermediate for the synthesis of various drugs and pharmacologically active compounds, contributing to the development of new medications and therapies.
Used in Agrochemical Production:
2-Pyrimidinecarbonitrile, 4-methoxy(6CI,9CI) is utilized in the production of agrochemicals, playing a role in the creation of substances that help protect and enhance crop yields.
Used in Dye Manufacturing:
2-Pyrimidinecarbonitrile, 4-methoxy(6CI,9CI) is employed in the manufacturing of dyes, contributing to the coloration and quality of various products.
Used in Industrial Chemicals Production:
2-Pyrimidinecarbonitrile, 4-methoxy(6CI,9CI) is also used in the production of other industrial chemicals, highlighting its broad applicability across different sectors.
Used in Research and Development:
2-Pyrimidinecarbonitrile, 4-methoxy(6CI,9CI) serves as a building block in research and development for the construction of novel compounds with potential therapeutic properties, further expanding its utility in scientific innovation.

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 17758-55-3 4-Methoxypyrimidine 1-oxide 
• 557-21-1 zinc(II) cyanide 
• 22536-63-6 2-chloro-4-methoxypyrimidine 
• 557-21-1 dicyanozinc 

Relevant academic research and scientific papers

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

SUBSTITUTED PYRIDINES AND METHOD OF USE

The invention discloses compounds of Formula (I) wherein X, R1, R2, and R3 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

3-Quinuclidinol as a nucleophilic catalyst for the cyanation of 2-chloropyrimidines

3-Quinuclidinol serves as an effective nucleophilic catalyst for the preparation of 2-cyanopyrimidines by cyanation of 2-chloropyrimidines with potassium cyanide in good yields.

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)